Last updated: 2026-09-16 09:06:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
DaVita Inc. (DVA) operates in the SERVICES-MISC HEALTH & ALLIED SERVICES, NEC sector and is listed on NYSE. The stock is currently priced at $190,00, with a market capitalisation of $12,08B and a P/E ratio of 14,37. Over the past 52 weeks, its price has ranged from $101,00 to $247,49. This page covers its latest market performance, valuation, price trends and company information.
$12,08B | |
$190,00 | |
$247,49 | |
$10,22 | |
$190,90 | |
7,00 | |
819,76K | |
14,37 | |
$247,49 | |
$101,00 | |
2,65% | |
-- |
DaVita Inc. (DVA) is trading at $190,00 in pre-market trading as of 2026-09-16 08:03:00, down 0,47% ($0,90) from the previous close of $190,90
Pre-market trading shows how investors are pricing DVA before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, DaVita Inc. (DVA) moved from $183,99 to $190,00, representing a gain of 3,27% ($6,01).
The stock traded between $176,82 and $191,40 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 643,70 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 60,8%
DVA is currently trading at $190,00, placing it 60,8% of the way from its 52-week low of $101,00 to its 52-week high of $247,49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
| Industry | SERVICES-MISC HEALTH & ALLIED SERVICES, NEC |
| Employees | 78000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of DaVita Inc. (DVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.